

Select Outpatient COVID-19 Therapeutics

COVID-19 Antiviral Product	Mechanism of Action	Administration Route
Ritonavir-boosted nirmatrelvir (Paxlovid)	protease inhibitor	Oral
Remdesivir	nucleoside analogue	Intravenous (3 days for outpatient)
Molnupiravir	mutagenic nucleoside analogue	Oral
Sotrovimab	anti-SARS-COV-2 monoclonal antibody	Intravenous
Casirivimab/Imdevimab (REGEN-COV)	anti-SARS-COV-2 monoclonal antibody	Intravenous; subcutaneous
Bamlanivimab/ Etesevimab	anti-SARS-COV-2 monoclonal antibody	Intravenous
Tixagevimab/ Cilgavimab (Evusheld)	anti-SARS-COV-2 monoclonal antibody	Two intramuscular injections
Pre-Exposure Prophylaxis		